Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies
Clinical Snapshot
PICO Framework
| P — Population | Adults with type 2 diabetes mellitus |
| I — Intervention | Tirzepatide therapy |
| C — Comparator | Control groups (various comparators including other antidiabetic medications) |
| O — Outcomes | Glycated hemoglobin (HbA1c) reduction, weight loss, body mass index decrease, proportion achieving HbA1c <7%, categorical weight loss thresholds |
Bottom Line
This systematic review of 89,296 patients demonstrates that tirzepatide achieves clinically meaningful improvements in both glycemic control and weight management in real-world settings. The 0.91% HbA1c reduction and 9.7 kg weight loss align with clinical trial efficacy, with nearly two-thirds of patients reaching target HbA1c <7%. While the included observational studies carry moderate to serious bias, the consistency with randomized controlled trial data and the substantial sample size strengthen confidence in these findings. For Australian clinicians, this real-world evidence supports tirzepatide as an effective option for patients with type 2 diabetes requiring dual glycemic and weight management benefits, though individual patient factors and cost-effectiveness considerations remain important in treatment selection.
Key Findings
P Value: Not reported in abstract
Effect Size: Weight loss of 9.7 kg (95% CI: -14.05 to -5.35); BMI decrease of 2.09 kg/m² (95% CI: -3.27 to -0.92)
Primary Outcome: HbA1c reduction of 0.91% (95% CI: -1.04 to -0.79)
Nnt Or Sensitivity: 64% achieved HbA1c <7%; 47% achieved ≥5% weight loss; 23% achieved ≥10% weight loss
Confidence Interval: All primary outcomes reported with 95% confidence intervals
Clinical Application
High feasibility given real-world evidence base, though cost considerations and PBS listing status may affect accessibility Relevant to Australian practice where tirzepatide is TGA-approved; real-world effectiveness data supports clinical decision-making within RACGP diabetes management guidelines Adults with type 2 diabetes in real-world clinical settings, particularly those requiring both glycemic control and weight management
Abstract
A systematic review and meta-analysis of real-world studies on tirzepatide is essential to strengthen evidence of its effectiveness in improving glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes. 13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92). Overall, 64% of tirzepatide users reached HbA1c <7%. Furthermore, tirzepatide lowered HbA1c (mean difference [MD] -0.38%; 95% CI: -0.44 to -0.33) and body weight (MD -6.27 kg; 95% CI: -9.22 to -0.33) more than the control. 47%, 23%, 9%, and 4% of tirzepatide users lost ≥5%, ≥10%, ≥15%, and ≥ 20% of their baseline weight, respectively. Tirzepatide's effects on HbA1c and weight in observational studies support clinical trial findings.
References
- 1.Kamrul-Hasan, A. B. M., Chatterjee, S., Nagendra, L., Dutta, D., & Pappachan, J. M. (2026). Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf238
Related Research
European journal of radiology
A CT-based deep learning model to differentiate between benign and malignant adrenal lesions
3 Aug 2026
Journal of chemical information and modeling
A Unified Molecular Graph and Protein Language Model Framework for Predicting Human Drug-Hormone Receptor Interactions with Structure-Aware Validation
28 July 2026
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Differential effects of hormone therapy formulations on Parkinson's disease risk: a systematic review and meta-analysis
23 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service